Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013;2013:732047.
doi: 10.1155/2013/732047. Epub 2013 Aug 20.

Neoadjuvant Chemotherapy and Targeted Therapy in Breast Cancer: Past, Present, and Future

Affiliations
Free PMC article
Review

Neoadjuvant Chemotherapy and Targeted Therapy in Breast Cancer: Past, Present, and Future

Simon P Gampenrieder et al. J Oncol. .
Free PMC article

Abstract

Traditionally, neoadjuvant treatment for breast cancer was preserved for locally advanced and inflammatory disease, converting an inoperable to a surgical resectable cancer. In recent years, neoadjuvant therapy has become an accepted treatment option also for lower tumor stages in order to increase the rate of breast conserving therapy and to reduce the extent of surgery. Furthermore, treatment response can be monitored, and therefore, patient compliance may be increased. Neoadjuvant trials, additionally, offer the opportunity to evaluate new treatment options in a faster way and with fewer patients than large adjuvant trials. Compared to the metastatic setting, the issue of acquired resistance and pretreatments, which may distort treatment efficacy, can be avoided. New trial designs like window-of-opportunity trials or postneoadjuvant trials provide the chance to identify tumor sensitivity or to overcome tumor resistance in early tumor stages. In particular, in HER2-positive breast cancer, the neoadjuvant approach yielded great successes. The dual HER2 blockade with trastuzumab and pertuzumab recently showed the highest pCR rates ever reported. Many new drugs are in clinical testing with the aim to further increase pCR rates. Whether this endpoint really represents a surrogate for long-term outcome is not answered yet and will be discussed in this review.

Similar articles

See all similar articles

Cited by 24 articles

See all "Cited by" articles

References

    1. Rastogi R, Anderson SJ, Bear HD. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. Journal of Clinical Oncology. 2008;26(16):p. 2793. - PubMed
    1. Van der Hage JA, Van de Velde CJH, Julien J-P, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for research and Treatment of Cancer Trial 10902. Journal of Clinical Oncology. 2001;19(22):4224–4237. - PubMed
    1. Mauri D, Pavlidis N, Ioannidis JPA. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. Journal of the National Cancer Institute. 2005;97(3):188–194. - PubMed
    1. Greil R. The still long and winding road to neoadjuvant sytemic therapy as the standard of care in breast cancer. Breast Care. 2006;1(6):352–357.
    1. Hutcheon AW, Heys SD, Sarkar TK, et al. Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial. Breast Cancer Research and Treatment . 2003;82(supplement 1):p. S6.
Feedback